Baloxavir marboxil

Baloxavir marboxil
Clinical data
Trade names	Xofluza
Other names	BXM (S-033188), BXA (S-033447)
AHFS/Drugs.com	Monograph
MedlinePlus	a618062
License data	EU EMA: by INN; US DailyMed: Baloxavir_marboxil; US FDA: Xofluza;
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth
ATC code	J05AX25 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name ({(12aR)-12-[(11S)-7,8-Difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f] [1,2,4]triazin-7-yl}oxy)methyl methyl carbonate;
CAS Number	1985606-14-1;
PubChem CID	124081896;
DrugBank	DB13997;
ChemSpider	59718643;
UNII	505CXM6OHG;
KEGG	D11021;
CompTox Dashboard (EPA)	DTXSID601027758 ;
Chemical and physical data
Formula	C27H23F2N3O7S
Molar mass	571.55 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OCOC(C(C=C1)=O)=C(N1N([C@@H]2C3=CC=CC=C3SCC4=C(F)C(F)=CC=C24)[C@@]5([H])N6CCOC5)C6=O)OC;
	InChI InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1; Key:RZVPBGBYGMDSBG-GGAORHGYSA-N;

Baloxavir marboxil, sold under the brand name Xofluza, is an antiviral medication for treatment of influenza A and influenza B.^[4] It was approved for medical use both in Japan and in the United States in 2018,^[7]^[8]^[9] and is taken as a single dose by mouth.^[4] It may reduce the duration of flu symptoms by about a day, but is prone to selection of resistant mutants that render it ineffectual.^[10]^{[unreliable medical source?]}

Baloxavir marboxil was developed as a prodrug strategy, with its metabolism releasing the active agent, baloxavir acid (BXA). Baloxavir acid then functions as enzyme inhibitor, targeting the influenza virus' cap-dependent endonuclease activity, used in "cap snatching" by the virus' polymerase complex, a process essential to its life-cycle.^[11]

The most common side effects of baloxavir marboxil include diarrhea, bronchitis, nausea, sinusitis, and headache.^[12]

The US Food and Drug Administration (FDA) considers baloxavir marboxil to be a first-in-class medication.^[13]

^ ^a ^b "Xofluza Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 2 March 2020. Archived from the original on 13 March 2020. Retrieved 16 August 2020.
^ "Xofluza Product information". Health Canada. 25 April 2012. Archived from the original on 12 August 2022. Retrieved 29 May 2022.
^ "Summary Basis of Decision (SBD) for Xofluza". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
^ ^a ^b ^c Cite error: The named reference Xofluza FDA label was invoked but never defined (see the help page).
^ Cite error: The named reference Xofluza EPAR was invoked but never defined (see the help page).
^ "Xofluza Product information". Union Register of medicinal products. Retrieved 3 March 2023.
^ "FDA approves new drug to treat influenza" (Press release). U.S. Food and Drug Administration (FDA). 24 October 2018. Archived from the original on 24 October 2019. Retrieved 23 October 2019. This article incorporates text from this source, which is in the public domain.
^ Cite error: The named reference FDA approval 2018 was invoked but never defined (see the help page).
^ Cite error: The named reference FDA approval 2019 was invoked but never defined (see the help page).
^ "Baloxavir Marboxil for Uncomplicated Influenza: Mechanism of Action & Side Effects". Huateng Pharma. Archived from the original on 24 February 2021. Retrieved 29 May 2020.
^ Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S, Baba K, et al. (December 2018). "In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit". Antiviral Res. 160: 109–117. doi:10.1016/j.antiviral.2018.10.008. PMID 30316915.
^ Cite error: The named reference FDA PR 20201123 was invoked but never defined (see the help page).
^ New Drug Therapy Approvals 2018 (PDF) (Report). U.S. Food and Drug Administration (FDA). January 2019. Archived from the original on 17 September 2020. Retrieved 16 September 2020. This article incorporates text from this source, which is in the public domain.

[Xofluza_APMDS-1] "Xofluza Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 2 March 2020. Archived from the original on 13 March 2020. Retrieved 16 August 2020.

[2] "Xofluza Product information". Health Canada. 25 April 2012. Archived from the original on 12 August 2022. Retrieved 29 May 2022.

[3] "Summary Basis of Decision (SBD) for Xofluza". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.

[Xofluza_FDA_label-4] Cite error: The named reference Xofluza FDA label was invoked but never defined (see the help page).

[Xofluza_EPAR-5] Cite error: The named reference Xofluza EPAR was invoked but never defined (see the help page).

[6] "Xofluza Product information". Union Register of medicinal products. Retrieved 3 March 2023.

[FDA_PR_20181024-7] "FDA approves new drug to treat influenza" (Press release). U.S. Food and Drug Administration (FDA). 24 October 2018. Archived from the original on 24 October 2019. Retrieved 23 October 2019. This article incorporates text from this source, which is in the public domain.

[FDA_approval_2018-8] Cite error: The named reference FDA approval 2018 was invoked but never defined (see the help page).

[FDA_approval_2019-9] Cite error: The named reference FDA approval 2019 was invoked but never defined (see the help page).

[10] "Baloxavir Marboxil for Uncomplicated Influenza: Mechanism of Action & Side Effects". Huateng Pharma. Archived from the original on 24 February 2021. Retrieved 29 May 2020.

[11] Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S, Baba K, et al. (December 2018). "In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit". Antiviral Res. 160: 109–117. doi:10.1016/j.antiviral.2018.10.008. PMID 30316915.

[FDA_PR_20201123-12] Cite error: The named reference FDA PR 20201123 was invoked but never defined (see the help page).

[13] New Drug Therapy Approvals 2018 (PDF) (Report). U.S. Food and Drug Administration (FDA). January 2019. Archived from the original on 17 September 2020. Retrieved 16 September 2020. This article incorporates text from this source, which is in the public domain.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]